No Data
Semiconductor Surge: How Sustainable Is the Rally?
BYD: In Q1, revenue and net profit both saw growth, with the New energy Fund driving record performance.
BYD Q1 revenue and net profit both increased: New energy Fund driven record performance, expanding production to prepare for Global market. Key points: Strong performance growth: Q1...
China Mulls Exempting Select U.S. Goods From 125% Tariffs - Report
Jiangsu Hengrui Pharmaceuticals: Authorized revenue becomes the "accelerator" for performance.
Personnel, products, and research and development are gradually becoming Global.
China Calls on U.S. to Lift All Unilateral Tariffs, Denies Talks
The upfront payment for the new ADC drug has boosted revenue, Jiangsu Hengrui Pharmaceuticals' Q1 revenue increased by 20.14% year-on-year, and net income increased by 36.9% | Earnings Reports insights.
In Q1, Jiangsu Hengrui Pharmaceuticals' revenue increased by 20.14% year-on-year, net income attributable to the parent company increased by 36.9%, and net income after deductions increased by 29.35% year-on-year. The significant increase in net income was primarily due to the company receiving a $75 million upfront payment for external licensing.
